3 terminated. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
| Phase 2 | 2 | Terminated 2 |
Follow ESSA Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC Enzalutamide, EPI-7386 with Enzalutamide - Prostate Cancer | Phase 1 / Phase 2 | Terminated | ESSA Pharmaceuticals | 77 | 2021-12-21 | 2025-02-28 |
| Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer EPI-7386 (QD), EPI-7386 (BID), Abiraterone acetate - Prostate Cancer | Phase 1 | Terminated | ESSA Pharmaceuticals | 71 | 2020-06-23 | 2025-02-28 |
| Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer EPI-506 - Prostatic Neoplasms, Genital Neoplasms, Male | Phase 1 / Phase 2 | Terminated | ESSA Pharmaceuticals | 28 | 2015-10-01 | 2018-03-01 |
Prostatic Neoplasms (3) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Prostatic Diseases (1)
Abiraterone Acetate (1) · BID protein, human (1) · EPI-506 (1) · apalutamide (1) · enzalutamide (1)
Canada (3) · United States (3) · Australia (1)
Frank Perabo, MD, PhD (1) · Kim N. Chi, MD (1) · Robert B. Montgomery, MD (1)